Featured
Lead report
Taysha Gene Therapies Plunges on $200M Stock Offering at $6 Per Share
Taysha Gene Therapies announced a $200 million public offering at $6 per share, causing a sharp after-hours selloff. The article analyzes the dilutive financing, pipeline progress, and investor concerns.
Syntax Bio Closes $14.4M Series A, Adds New CBO and Board Members
Gene editing company Syntax Bio expands its Series A to $14.4 million, appoints a new Chief Business Officer and two independent directors. Funds will advance metabolic disease gene therapy pipeline and technology platform.
Biogen Acquires RayThera for Up to $1 Billion: Strategic Expansion in Neuroscience
Biogen has agreed to acquire privately held biotech RayThera for up to $1 billion, gaining a preclinical candidate targeting Alzheimer's and other neurodegenerative diseases. The deal underscores Biogen's deepening commitment to neuroscience.
More Related Articles
Moderna Evaluates German Production Facilities as BioNTech Shuts Down Plants: mRNA Vaccine Industry in Flux
Moderna is reportedly assessing the acquisition of production facilities in Germany, while BioNTech plans to close some plants. This shift reflects post-pandemic capacity rebalancing in the mRNA vaccine sector, offering insights for U.S. biotech investment strategies.
This Week's Blockbuster Deals: GSK, Incyte, Ingredion, OpenAI Lead US Stock Market Trends
A deep dive into key US stock market moves this week, including GSK's consumer health divestiture, Incyte's acquisition of MorphoSys, Ingredion's South American business sale, and OpenAI's $40 billion funding round, along with updates on Tesla, Apple, and Amazon.
Sanofi's Tzield Receives FDA Approval for Stage 3 Type 1 Diabetes Treatment, Boosting US Stock
Sanofi announced FDA approval of Tzield for stage 3 type 1 diabetes, filling an immunomodulatory therapy gap. Market response is positive, with analysts projecting peak sales of $2-3 billion, strengthening the company's metabolic disease pipeline.
